This competitive renewal will continue our work on understanding the pathophysiology of cryptococcal disease in the central nervous system (CNS) from the yeast's perspective. Cryptococcus neoformans and Cryptococcus gattii represent encapsulated basidiomycetous yeasts that produce a million cases of disease per year and an estimated 600, 000 deaths with present treatment. Cryptococcus is neurotropic causing cryptococcal meningoencephalitis, the life-threatening stage of infection for this disease.
Aim 1 will not only define the in vivo transcriptional response of Cryptococcus clinical isolates to human CNS, but it will also identify gene(s) and gene pathway(s) that contribute significantly to the yeasts ability to grow and survive in the CNS. Furthermore, we will characterize these responses based on patient outcome (more or less virulent), genotype, and additional variables to identify conserved genes that may contribute to strain adaptation in the CNS to produce disease. The impact of these genes will be assessed using robust assays that examine their impact on survival in human CSF, virulence determinants, survival in animal models.
Aim 2 continues our focused analysis on how core metabolism promotes cryptococcal growth and survival in the CNS by investigating carbon and nitrogen metabolism. This application integrates advanced molecular techniques, insights of the fungus through our prior studies, and close linkage to human disease and outcome. Its goal is to dissect, identify, and validate "weak" spots in the yeast's stress response in the CNS and thus provides new target (s) for antifungal strategies, which continue to substantially fail in the treatment of this life-threatening fungal infection.
Cryptococcal meningitis occurs in approximately 1 million cases per year with an estimated mortality of 600,000 deaths per year. This is primarily related to our enlarging immunocompromised populations with HIV and transplant recipients. In resource-limited countries, the mortality can be over 50% and even in countries with advanced healthcare, mortality reaches 20-30% with present therapies. Therefore, this application attempts to understand how Cryptococcus, this encapsulated yeast, causes disease in the central nervous system. Through these studies we hope to find important genetic targets or pathways, which could be used to find new antifungal compounds for eventual drug development.
|Perfect, John R; Bicanic, Tihana (2015) Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genet Biol 78:49-54|
|Inoue, Makoto; Arikawa, Tomohiro; Chen, Yu-Hsun et al. (2014) T cells down-regulate macrophage TNF production by IRAK1-mediated IL-10 expression and control innate hyperinflammation. Proc Natl Acad Sci U S A 111:5295-300|
|Perfect, John R (2014) Cryptococcosis: a model for the understanding of infectious diseases. J Clin Invest 124:1893-5|
|Rosentul, Diana C; Plantinga, Theo S; Farcas, Marius et al. (2014) Role of autophagy genetic variants for the risk of Candida infections. Med Mycol 52:333-41|
|Holmer, Stephanie M; Evans, Kathy S; Asfaw, Yohannes G et al. (2014) Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis. Infect Immun 82:683-93|
|Frazzitta, Aubrey E; Vora, Haily; Price, Michael S et al. (2013) Nitrogen source-dependent capsule induction in human-pathogenic cryptococcus species. Eukaryot Cell 12:1439-50|
|Johnson, Melissa D; Plantinga, Theo S; van de Vosse, Esther et al. (2012) Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin Infect Dis 54:502-10|
|Geunes-Boyer, Scarlett; Beers, Michael F; Perfect, John R et al. (2012) Surfactant protein D facilitates Cryptococcus neoformans infection. Infect Immun 80:2444-53|
|Rosentul, D C; Plantinga, T S; Scott, W K et al. (2012) The impact of caspase-12 on susceptibility to candidemia. Eur J Clin Microbiol Infect Dis 31:277-80|
|Plantinga, Theo S; Johnson, Melissa D; Scott, William K et al. (2012) Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis 205:934-43|
Showing the most recent 10 out of 24 publications